Clinical Trial Growth Has Outpaced the Systems Meant to Police It
Clinical trials now number more than one million worldwide, yet expansion has not translated into cleaner evidence or more reliable reporting. A 2026 review in AME clinical trials review argues that the field has accumulated too much redundancy, too much waste, and too little reproducibility, even as the basic architecture of trial science has become more sophisticated.
The central problem is not a shortage of studies. It is the uneven quality of the studies that continue to be launched, completed, published, and then reused to shape care. When trial volume rises faster than oversight, weak design can masquerade as progress, and underpowered findings can enter the medical record with undue influence.
Registration, Protocols, and Statistical Plans Still Leave Too Much Room for Drift
One of the most persistent weaknesses lies in transparency before enrollment begins. Prospective registration remains incomplete, trial results still go unreported, and access to protocols and statistical analysis plans remains limited. Registration quality also remains inconsistent, which makes it harder to determine whether outcomes were specified in advance or adjusted after data became available.
Those failures matter because they affect the credibility of the entire trial chain. A protocol is supposed to lock in the logic of the study, while a statistical analysis plan should protect the analysis from opportunistic changes. When either document is missing, incomplete, or posted only after the fact, the boundary between planned research and narrative reconstruction begins to blur.
Several policy initiatives have improved the environment, but the review makes clear that current requirements still leave large gaps. Trial registration platforms often lack core mandatory elements, and the review frames this as a structural weakness rather than a minor administrative flaw. If the trial is not registered well at the outset, every later claim becomes harder to audit.
Registration before ethical approval would tighten that front end immediately.
Bias, Underpowered Samples, and Integrity Failures Continue to Distort Evidence
The review describes a trial ecosystem in which many studies still carry a high risk of bias, design flaws, or sample sizes too small to support firm conclusions. Underpowered studies are especially dangerous because they can generate unstable estimates, inflate uncertainty, and invite overinterpretation when a result happens to cross a statistical threshold. A seemingly positive trial can therefore be little more than a fragile signal drawn from too few participants.
Dishonesty adds a separate and more corrosive layer. Data fabrication and retractions continue to complicate interpretation, especially when a study has already influenced meta-analyses, guidelines, or clinical enthusiasm before the problem is exposed. Once erroneous data are absorbed into the literature, later corrections rarely erase their influence fully.
Peer review also receives sharp scrutiny. In its current form, appraisal is often concentrated too late in the publication process and may underuse opportunities for critical assessment at the pre-submission, preprint, and post-publication stages. A narrower review window allows avoidable flaws to pass through untouched, especially when methodological weaknesses are subtle rather than dramatic.
Reporting Standards Are Commonly Invoked but Inconsistently Applied
The review places heavy emphasis on the uneven use of CONSORT and SPIRIT reporting standards. Journals frequently endorse these frameworks, but endorsement does not always mean enforcement. Researchers may face a significant burden in applying the guidelines, while editors and reviewers may apply them unevenly or treat them as optional ornaments rather than basic infrastructure.
Spin reporting compounds the problem. Results can be framed more favorably than the data justify, especially when primary endpoints are neutral, subgroup findings are overstated, or marginal effects are narrated as clinically decisive. Public dissemination can then amplify the distortion, carrying an oversold message beyond the journal page and into media coverage, patient expectations, and policy discussions.
The consequence is not merely semantic. Misleading presentation can alter how evidence is perceived long before replication or independent validation is possible.
AI Is Entering Trial Workflows Faster Than Disclosure Standards Can Keep Up
Artificial intelligence now reaches nearly every step of the trial process, including risk-of-bias assessment and integrity review. The speed of adoption is unsurprising; AI can sift large volumes of text, detect patterns, and support review tasks that would otherwise absorb substantial human time. Yet the review identifies two especially troubling gaps: inadequate disclosure of AI use and insufficient human verification.
A tool that accelerates screening or analysis is only as trustworthy as the oversight surrounding it. If AI contributes to a judgment but its role is not clearly disclosed, readers cannot assess where human interpretation ended and automated inference began. If human verification is weak, errors may pass through at scale and retain a veneer of technical authority.
The concern is not hypothetical. Clinical trials depend on traceability at every stage, and AI can obscure traceability if deployed carelessly. Transparent disclosure and clear human review are therefore not optional extras; they are part of the evidentiary chain.
Eighteen Suggestions and 19 Strategies Aim to Repair the Trial Ecosystem
The review proposes 18 suggestions and 19 strategies to improve trial quality, transparency, and accountability. Among them are requiring registration before ethical approval, founding journals devoted to statistically negative trials, and building an integrated feedback-and-fixing mechanism for trial quality. Each proposal addresses a different point of failure, from the front-end design phase to downstream publication practices.
A journal dedicated to negative trials could reduce publication bias by creating a legitimate venue for studies that do not produce positive effects. An integrated quality feedback system could identify recurring design or reporting problems and push those lessons back into future trials rather than letting the same mistakes recur across institutions and sponsors. These are not cosmetic reforms. They target the incentive structure that still favors excitement over rigor.
The strongest thread running through the review is simple. Clinical trials can only improve care when their methods, reporting, and interpretation remain visible enough to inspect. The field now has more trials than ever, but scale alone does not equal reliability, and without stronger transparency, better peer review, and clearer AI governance, the literature will continue to produce more noise than trustworthy signal.